AACR 2023 | How can immunotherapies successfully target MSS colorectal cancer?
Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses strategies to enhance the efficacy of immunotherapies in microsatellite stable (MSS) colorectal cancer, a subtype that is typically immunologically cold. Targeting pathways such as VEGF and developing TKIs may provide a path for immunotherapies to be efficacious. Cellular therapies such as CAR-T cell therapies and neoantigen vaccines with checkpoint inhibition additionally represent promising strategies on the horizon. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah. So, there are many different options here. This is the huge question in colorectal cancer as the majority of the microenvironment is very cold. And so, I think we highlight here one strategy where we try to change the tumor microenvironment. But there are others that look at the VEGF pathway, look at novel TKI targeting, also look at CAR-T-cells and actually the development of Neo-antigen vaccine-based opportunities as well to in combination with checkpoint inhibition...
Yeah. So, there are many different options here. This is the huge question in colorectal cancer as the majority of the microenvironment is very cold. And so, I think we highlight here one strategy where we try to change the tumor microenvironment. But there are others that look at the VEGF pathway, look at novel TKI targeting, also look at CAR-T-cells and actually the development of Neo-antigen vaccine-based opportunities as well to in combination with checkpoint inhibition. So, all of these rationale trying to find a way to turn this cold environment into a hot environment that’s responsive to immunotherapy.
Read more...
